Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Volitionrx Ltd (VNRX)

Volitionrx Ltd (VNRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 133,862
  • Shares Outstanding, K 37,814
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,010 K
  • 60-Month Beta 0.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.11
  • Low Estimate -0.12
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.90 +20.69%
on 06/21/19
3.60 -2.78%
on 07/19/19
+0.53 (+17.85%)
since 06/19/19
3-Month
2.90 +20.69%
on 06/21/19
3.63 -3.45%
on 04/30/19
+0.11 (+3.24%)
since 04/18/19
52-Week
1.44 +143.06%
on 08/02/18
3.63 -3.45%
on 04/30/19
+1.53 (+77.66%)
since 07/19/18

Most Recent Stories

More News
VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun...

VNRX : 3.50 (-1.13%)
VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately $1.4 million...

VNRX : 3.50 (-1.13%)
VolitionRX Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 9, 2019 / VolitionRX Ltd. (NYSEMKT: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM Eastern Time.

VNRX : 3.50 (-1.13%)
VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2019. Volition management will host a conference call...

VNRX : 3.50 (-1.13%)
VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a contract under the previously announced Memorandum...

VNRX : 3.50 (-1.13%)
VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update

VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call on Thursday, May 9 at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter...

VNRX : 3.50 (-1.13%)
Recent Analysis Shows Roku, AMERI, Kforce, VolitionRX, Xinyuan Real Estate, and TSR Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Roku, Inc. (NASDAQ:ROKU),...

ROKU : 106.85 (-1.99%)
TSRI : 4.46 (+2.06%)
VNRX : 3.50 (-1.13%)
AMRH : 0.35 (-1.69%)
XIN : 4.27 (+1.67%)
KFRC : 35.82 (+0.93%)
VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") hosted a Capital Markets Day at the New York Stock Exchange today to update interested parties on its recent progress. Volition has also issued a Company...

VNRX : 3.50 (-1.13%)
VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") through its wholly-owned subsidiary, Belgian Volition SPRL, with Texas A&M University,...

VNRX : 3.50 (-1.13%)
VolitionRx Limited Extends Clinical Trial Program in Lung Cancer

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a non-binding Memorandum of Understanding, through...

VNRX : 3.50 (-1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade VNRX with:

Business Summary

Volition RX Ltd is a life sciences company engaged in developing a range of blood-based epigenetic cancer diagnostic tests. Its tests are designed to detect the nucleosome patterns that are specific to cancer in the blood, and identify some of the major nucleosome varieties that differ between cancer...

See More

Key Turning Points

2nd Resistance Point 3.65
1st Resistance Point 3.57
Last Price 3.50
1st Support Level 3.45
2nd Support Level 3.41

See More

52-Week High 3.63
Last Price 3.50
Fibonacci 61.8% 2.79
Fibonacci 50% 2.53
Fibonacci 38.2% 2.27
52-Week Low 1.44

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar